12:00 AM
 | 
Sep 30, 2013
 |  BioCentury  |  Finance

Value ad(imab)

Adimab VCs will be in the black by next year thanks to tech transfer deals

Adimab LLC's VCs expect to be in the black starting next year thanks to the antibody company's three recent tech transfer deals, including one last week with Novo Nordisk A/S. Adimab hopes the deals will mark the start of a steady flow of dividend checks to its investors.

CEO Tillman Gerngross said Adimab's business development strategy from the start has been to deploy its yeast-based antibody discovery technology as widely as possible (see BioCentury, March 31, 2008).

Adimab was founded in 2007 and after two years began signing narrowly focused service agreements. The tally is 23 customers, most recently including Celgene Corp. and Innovent Biologics Inc.

According to Terry McGuire of Polaris Ventures, the hope was customers would be impressed enough to...

Read the full 609 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >